{"created":"2022-02-22T04:10:43.233517+00:00","id":2016002,"links":{},"metadata":{"_buckets":{"deposit":"3b9b2446-e8d8-45a1-b218-ae54c5306627"},"_deposit":{"id":"2016002","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"2016002"},"status":"published"},"_oai":{"id":"oai:u-ryukyu.repo.nii.ac.jp:02016002","sets":["1642838163960:1642838198944:1642838199408:1642838208619","1642838403551:1642838412624"]},"author_link":[],"item_1617186331708":{"attribute_name":"Title","attribute_value_mlt":[{"subitem_1551255647225":"[原著］Predicting factors and efficacy of interferon alpha therapy in patients with liver cirrhosis associated with HCV infection","subitem_1551255648112":"ja"}]},"item_1617186419668":{"attribute_name":"Creator","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Nakasone, Hiroki","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Sgkuawa, Hiroshi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Nakayoshi, Tmofumi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kawakami, Yuko","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kinjo, Fukunori","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Saito, Atushi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Yamashiro, Akiko","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Nakayoshi, Tmokuni","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Ikema, Minoru","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Hirayama, Yoshikatsu","creatorNameLang":"en"}]}]},"item_1617186476635":{"attribute_name":"Access Rights","attribute_value_mlt":[{"subitem_1522299639480":"open access","subitem_1600958577026":"http://purl.org/coar/access_right/c_abf2"}]},"item_1617186499011":{"attribute_name":"Rights","attribute_value_mlt":[{"subitem_1522650717957":"ja","subitem_1522651041219":"琉球医学会"}]},"item_1617186609386":{"attribute_name":"Subject","attribute_value_mlt":[{"subitem_1522299896455":"en","subitem_1522300014469":"Other","subitem_1523261968819":"interferon alpha"},{"subitem_1522299896455":"en","subitem_1522300014469":"Other","subitem_1523261968819":"liver cirrhosis"},{"subitem_1522299896455":"en","subitem_1522300014469":"Other","subitem_1523261968819":"hepatitis type C"}]},"item_1617186626617":{"attribute_name":"Description","attribute_value_mlt":[{"subitem_description":"The present study examined the efficacy and the predicting factors of response to interferon (IFN) alpha in patients with liver cirrhosis associated with hepatitis type C virus infection (LC type C). Sixty-seven patients were treated with IFN alpha and were classified into 2 Groups. Group 1 : Patients with liver cirrhosis, showing histological liver cirrhosis or chronic active hepatitis with lobular disorganization. Group 2 : Patients with chronic hepatitis, showing histological chronic persistent hepatitis or chronic active hepatitis without lobular disorganization. Sustained response to IFN was obtained in 5/17 (29.4%) and 24/50 (48%) of patients in Group 1 and Group 2, respectively. However, the difference was not significant. All patients in Group 2 showed a significant decrease in alanine aminotransferase (ALT) levels during the treatment, whereas 5 of the 17 patients in Group 1 showed no response. All sustained responders in Group 1 who were tested for serum HCV-RNA titer showed low serum HCV-RNA titer, which was less than 10^7 copies/ml, while all except one patient of the non-responders of Group 1 showed above 10^8 copies/ml. It is said that patients with LC type C are more resistant to IFN treatment compared to those with chronic hepatitis type C. However, our findings suggest that even in patients with LC type C, low serum HCV-RNA levels might be associated with better response to IFN.","subitem_description_type":"Other"},{"subitem_description":"論文","subitem_description_type":"Other"}]},"item_1617186643794":{"attribute_name":"Publisher","attribute_value_mlt":[{"subitem_1522300295150":"ja","subitem_1522300316516":"琉球医学会"},{"subitem_1522300295150":"en","subitem_1522300316516":"Ryukyu Medical Association"}]},"item_1617186702042":{"attribute_name":"Language","attribute_value_mlt":[{"subitem_1551255818386":"eng"}]},"item_1617186920753":{"attribute_name":"Source Identifier","attribute_value_mlt":[{"subitem_1522646500366":"ISSN","subitem_1522646572813":"1346888X"},{"subitem_1522646500366":"ISSN","subitem_1522646572813":"0289-1530"},{"subitem_1522646500366":"NCID","subitem_1522646572813":"AN10369445"}]},"item_1617186941041":{"attribute_name":"Source Title","attribute_value_mlt":[{"subitem_1522650068558":"ja","subitem_1522650091861":"琉球医学会誌 = Ryukyu Medical Journal"}]},"item_1617187056579":{"attribute_name":"Bibliographic Information","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"1996","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3","bibliographicPageEnd":"121","bibliographicPageStart":"117","bibliographicVolumeNumber":"16"}]},"item_1617258105262":{"attribute_name":"Resource Type","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_1617265215918":{"attribute_name":"Version Type","attribute_value_mlt":[{"subitem_1522305645492":"VoR","subitem_1600292170262":"http://purl.org/coar/version/c_970fb48d4fbd8a85"}]},"item_1617605131499":{"attribute_name":"File","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","filename":"v16p117.pdf","mimetype":"application/pdf","url":{"objectType":"fulltext","url":"https://u-ryukyu.repo.nii.ac.jp/record/2016002/files/v16p117.pdf"},"version_id":"b0882217-5e64-459c-8f41-59cdf6b705a9"}]},"item_title":"[原著］Predicting factors and efficacy of interferon alpha therapy in patients with liver cirrhosis associated with HCV infection","item_type_id":"15","owner":"1","path":["1642838208619","1642838412624"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2010-07-02"},"publish_date":"2010-07-02","publish_status":"0","recid":"2016002","relation_version_is_last":true,"title":["[原著］Predicting factors and efficacy of interferon alpha therapy in patients with liver cirrhosis associated with HCV infection"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2022-10-31T07:48:27.583060+00:00"}